About this Research Topic
This Research Topic is intended to cover current knowledge regarding immune surveillance that impacts tumor development, prevention and treatment. Invited articles are intended to address humoral and cellular responses that may prevent or occur at various stages of tumor development, the range of structural changes that contribute to antigenicity and mechanisms of immune evasion and novel approaches to cancer detection and treatment that harness the immune response.
The problem to be addressed is how to harness the immune response to develop means to prevent, detect early or treat cancer. The research topics cover diagnostics, vaccines and novel immunotherapeutics for cancer. Advances to be covered include relevant technologies, tumor associated antigens and mutated neoantigen identification and novel means to induce a humoral and a cellular response .
We welcome manuscripts focusing on, but not limited to, the following themes:
• Humoral and cellular anti-tumor immune response
• Immune response as a biomarker for cancer diagnosis
• Vaccines for cancer prevention, interception, or treatment
• Tumor antigens for prevention versus therapy (shared neoantigens, mutated neoantigens)
• Novel strategies for immunotherapy and immunoprevention
Topic editor Dr. Olivera Finn is a member of the PDS Biotech, Immodulon, GeoVax, and Invectus advisory boards. All other Topic Editors declare no competing interests with regards to the Research Topic subject.
Dr. Olivera Finn dedicates the Co-Editorship of this Research Topic to the International Union of Immunological Societies (IUIS).
The problem to be addressed is how to harness the immune response to develop means to prevent, detect early or treat cancer. The research topics cover diagnostics, vaccines and novel immunotherapeutics for cancer. Advances to be covered include relevant technologies, tumor associated antigens and mutated neoantigen identification and novel means to induce a humoral and a cellular response .
We welcome manuscripts focusing on, but not limited to, the following themes:
• Humoral and cellular anti-tumor immune response
• Immune response as a biomarker for cancer diagnosis
• Vaccines for cancer prevention, interception, or treatment
• Tumor antigens for prevention versus therapy (shared neoantigens, mutated neoantigens)
• Novel strategies for immunotherapy and immunoprevention
Topic editor Dr. Olivera Finn is a member of the PDS Biotech, Immodulon, GeoVax, and Invectus advisory boards. All other Topic Editors declare no competing interests with regards to the Research Topic subject.
Dr. Olivera Finn dedicates the Co-Editorship of this Research Topic to the International Union of Immunological Societies (IUIS).
Keywords: immune surveillance, tumor antigens, autoantigens, immune evasion, immunotherapy, Society affiliation RT
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
